We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Topical fluticasone propionate: intervention and maintenance treatment options of atopic dermatitis based on a high therapeutic index.
- Authors
Korting, H.C.; Schöllmann, C.
- Abstract
Fluticasone propionate (FP), a medium potent glucocorticoid (class III) of carbothioate nature with a favourable benefit/risk ratio, has emerged as a standard medication for the topical treatment of inflammatory skin disorders, in particular atopic dermatitis (AD). FP is available as a 0.05% cream and a 0.005% ointment formulation. The glucocorticoid is characterized by high lipophilicity, high affinity binding to the glucocorticoid receptor and a rapid hepatic biotransformation. Though skin blanching following topical application of FP surpasses that given with glucocorticoids of medium strength, clinical trials show a low potential of FP for local and systemic adverse effects. Even in paediatric patients with AD as well as in difficult-to-treat areas like face, eyelids and intertriginous areas, FP proved to be both effective and safe. Thus, the therapeutic effects of FP clearly outweigh the unwanted effects. Correspondingly, a therapeutic index of 2.0 can be attributed to this glucocorticoid. In this respect, topical FP does not differ from other topical glucocorticoids with increased benefit-to-risk ratio, e.g. prednicarbate, methylprednisolone aceponate and mometasone furoate. However, randomized controlled trials do not only support conventional intervention but also innovative maintenance treatment.
- Subjects
THERAPEUTIC use of glucocorticoids; SKIN abnormalities treatment; ATOPIC dermatitis; DAIRY cream; OINTMENTS
- Publication
Journal of the European Academy of Dermatology & Venereology, 2012, Vol 26, Issue 2, p133
- ISSN
0926-9959
- Publication type
Article
- DOI
10.1111/j.1468-3083.2011.04195.x